EcoDrugPlus

Tumor Protein P53

Ensembl ID : ENSEEEG00000016191
Gene Symbol: TP53
4 Cross references
164 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSEEEG00000001329
Gene Symbol: TYR
4 Cross references
203 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSEEEG00000012190
Gene Symbol: TYR
4 Cross references
197 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSEEEG00000013099
Gene Symbol: TH
4 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSEEEG00000003918
Gene Symbol: TYK2
4 Cross references
196 Possible Orthologues:

Utrophin

Ensembl ID : ENSEEEG00000003274
Gene Symbol: UTRN
2 Cross references
254 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSEEEG00000021822
Gene Symbol: KRAS
4 Cross references
208 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2

Ensembl ID : ENSEEEG00000007110
Gene Symbol: AKT2
2 Cross references
199 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 3a

Ensembl ID : ENSEEEG00000007631
Gene Symbol: AKT3A
2 Cross references
203 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSEEEG00000016874
Gene Symbol: RELA
4 Cross references
201 Possible Orthologues:

V-Src Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog

Ensembl ID : ENSEEEG00000023251
Gene Symbol: SRC
4 Cross references
198 Possible Orthologues:

Vascular Endothelial Growth Factor Aa

Ensembl ID : ENSEEEG00000010467
Gene Symbol: VEGFAA
4 Cross references
180 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).